Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
More than 80% of U.S. physicians use AI in their work. AI is revealing new cardiac biomarkers and speeding drug discovery, with the healthcare AI market projected to reach $505.6 billion by 2033—but studies warn of bias and eroding critical thinking.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Researchers are developing gene therapy approaches for neurological disorders and head and neck conditions, using viral vectors and advanced delivery methods to treat brain tumors, Alzheimer's, and Parkinson's disease.
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07685301 |
Development and Validation of an AI Foundation Model for CNS Tumor Classification |
NOT_YET_RECRUITING | |
| NCT07620470 |
Spectral Precise Image Study for Brain Tumors |
RECRUITING | |
| NCT07599917 |
Diagnostic Performance and Quantitative Analysis of [18F]FET PET in Brain Tumours |
NOT_YET_RECRUITING | |
| NCT07595666 |
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. |
ENROLLING_BY_INVITATION | NA |
| NCT07530536 |
rTMS for Postoperative Brain Tumor Patients |
RECRUITING | NA |
| NCT07321262 |
Machine Learning to Predict Postoperative Pneumonia in Brain Tumor Patients |
COMPLETED | |
| NCT07274397 |
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma |
RECRUITING | NA |
| NCT07126821 |
A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data |
RECRUITING | |
| NCT06887673 |
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT06878469 |
SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence |
RECRUITING | NA |
